机构：[1]Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China[2]Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science and PUMC, Beijing 100730, China[3]THERANOSTICS Center forMolecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, 99437 Bad Berka, Germany[4]Department of Pediatric Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing Key Laboratory of Brain Tumor, Beijing 100730, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[5]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing Key Laboratory of Brain Tumor, Beijing 100730, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[6]Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892, USA
PurposeOptic pathway glioma (OPG) is a rare neoplasm that arises predominantly during childhood. Its location in a sensitive region involving the optic pathways, onset in young patients and controversial therapy choice make the management of OPG a challenge in paediatric neuro-oncology. In this study we assessed gastrin-releasing peptide receptor (GRPR)-targeted positron emission tomography (PET) imaging in children with OPG, and the application of a PET/MRI imaging-guided surgery navigation platform.MethodsEight children (five boys, mean age 8.81years, range 5-14years) with suspicion of optic pathway glioma on MRI were recruited. Written informed consent was obtained from all patients and legal guardians. Brain PET/CT or PET/MRI acquisitions were performed 30min after intravenous injection of 1.85MBq/kg body weight of Ga-68-NOTA-Aca-BBN(7-14). Four patients also underwent F-18-FDG brain PET/CT for comparison. All patients underwent surgical resection within 1week.ResultsAll 11 lesions (100%) in the eight patients showed prominent Ga-68-NOTA-Aca-BBN(7-14) uptake with excellent contrast in relation to surrounding normal brain tissue. Tumour-to-background ratios (SUVmax and SUVmean) were significantly higher for Ga-68-NOTA-Aca-BBN(7-14) than for F-18-FDG (28.45.59 vs. 0.47 +/- 0.11 and 18.3 +/- 4.99 vs. 0.35 +/- 0.07, respectively). Fusion images for tumour delineation were obtained in all patients using the PET/MRI navigation platform. All lesions were pathologically confirmed as OPGs with positive GRPR expression, and 75% were pilocytic astrocytoma WHO grade I and 25% were diffuse astrocytoma WHO grade II. There was a positive correlation between the SUV of Ga-68-NOTA-Aca-BBN(7-14) and the expression level of GRPR (r(2)=0.56, P<0.01, for SUVmax; r(2)=0.47, P<0.05, for SUVmean).Conclusion This prospective study showed the feasibility of Ga-68-NOTA-Aca-BBN(7-14) PET in children with OPG for tumour detection and localization. Ga-68-NOTA-Aca-BBN(7-14) PET/MRI may be helpful for assisting surgery planning in OPG patients with severe symptoms, GRPR-targeted PET has the potential to provide imaging guidance for further GRPR-targeted therapy in patients with OPG.
基金：
Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81701742]
第一作者机构：[1]Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China[2]Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science and PUMC, Beijing 100730, China[3]THERANOSTICS Center forMolecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, 99437 Bad Berka, Germany
共同第一作者：
通讯作者：
通讯机构：[1]Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China[2]Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science and PUMC, Beijing 100730, China[6]Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892, USA
推荐引用方式(GB/T 7714)：
Zhang Jingjing,Tian Yongji,Li Deling,et al.Ga-68-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma[J].EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.2019,46(10):2152-2162.doi:10.1007/s00259-019-04392-7.
APA：
Zhang, Jingjing,Tian, Yongji,Li, Deling,Niu, Gang,Lang, Lixin...&Chen, Xiaoyuan.(2019).Ga-68-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,46,(10)
MLA：
Zhang, Jingjing,et al."Ga-68-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma".EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 46..10(2019):2152-2162
医学